In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $5.38 per share, reflecting a decline of 23.4% compared to the same period last year.

Days before it was to go into effect, the Trump administration pushed back a U.S. customs rule threatening the supply of vital prescription drugs imported by millions of Americans. Under the rule, ...

"Modest rise" in hemoglobin concentration could still help in chronic anemia management ...

Target Price (Mid): ~$2,220Street Target: ~$1,330Potential Total Return: ~74%Annualized IRR: ~14% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation ...

Last week MAA ace writer, Emma Hall, introduced us to her piece on the ever increasing show biz influence on […] ...

My journey toward dialysis began in July 2024.My underlying condition, diabetes, worsened, and I had to be hospitalized. At ...

Eli Lilly extended its same-direction streak to three days, with ETF flows net negative on Wednesday, Oct. 21, at -$64.0 million. Twenty ...

Explore the big questions 340B rebate pilot raises as hospitals prepare for the Jan. 1 shift to upfront payments and rebate claims.

Republished from an article originally posted on AnswersNews on July 6, 2026Based on product-specific sales figures disclosed ...

A New Delhi drugmaker, India's fourth largest by its own count, that sells branded medicines and consumer health brands at ...

Andrew Heller writes that Halloween is nothing compared to how scary our politics have become.

台灣目前常見的降血糖藥物 SGLT2i（俗稱排糖藥），主要有三款：福適佳 (Forxiga)、恩排糖 (Jardiance)、可拿糖 (Canaglu)。不少病友常有疑問：「這三顆藥到底差在哪？如果想減重、改善心衰竭或慢性腎臟病，哪一顆效果最好？」 ...